Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
GALDERMA GROUP AG(GALDY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GALDY
11/06/2026: GALDY (3-star) is a STRONG-BUY. BUY for 15 days. Simulated Profits (11.09%). Updated daily EoD!
Galderma Group AG is a leading global pure-play dermatology company offering a diverse portfolio of medical, aesthetic, and consumer skincare products. The company’s primary strength lies in its high-margin injectable aesthetics segment, anchored by well-known brands like Restylane. Its growth story is tied to the increasing global demand for non-surgical cosmetic procedures and science-based skincare. Key risks include intense competition from established pharmaceutical giants and sensitivity to consumer spending habits. This stock may suit growth-oriented investors looking for exposure to the aesthetics market, though potential investors should closely monitor regulatory updates and market share performance against major industry competitors.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Galderma offers direct exposure to the high-growth medical aesthetics market. |
| Momentum investor | Mixed fit | Momentum is conditional on positive market sentiment following the IPO. |
| Value investor | Mixed fit | Valuation requires careful assessment of growth premiums in the pharma sector. |
| Dividend investor | Weak fit | The company is currently prioritizing reinvestment over dividend payouts. |
| Low-risk investor | Weak fit | The stock carries risks associated with market volatility and aesthetic industry trends. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | As a relatively new public company, the stock may experience significant price swings. |
| Valuation risk | Medium | Growth expectations are already baked into current valuations. |
| Competition risk (AbbVie/Botox) | High | Maintaining market share against established giants is critical for long-term value. |
| Business quality | Medium / high | Galderma possesses a specialized, high-margin portfolio. |
| Dividend income | Low | Income is not the primary investment goal for this equity. |
| Execution risk | Medium | Success depends on consistent innovation and effective global marketing. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 100.86% | Avg. Invested days 58 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 54.30B USD | Price to earnings Ratio 63.79 | 1Y Target Price 52.52 |
Price to earnings Ratio 63.79 | 1Y Target Price 52.52 | ||
Volume (30-day avg) 163.4K shares | Beta -0.11 | 52 Weeks Range 35.47 - 47.92 | Updated Date 11/08/2026 |
52 Weeks Range 35.47 - 47.92 | Updated Date 11/08/2026 | ||
Dividends yield (FY) 0.19% | Basic EPS (TTM) 0.73 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Injectable Aesthetics | Restylane, Dysport, and Sculptra. | This is the core profit driver, selling premium products for medical aesthetic procedures. |
| Dermatological Skincare | Cetaphil and clinical skincare. | This segment provides stable, recurring revenue from consumer-facing products. |
| Therapeutic Dermatology | Medical treatments for skin conditions. | This area serves as a specialized foundation, addressing medical skin health needs. |
Valuation
Trailing PE 63.79 | Forward PE 35.97 | Enterprise Value 56.70B | Price to Sales(TTM) 9.17 |
Enterprise Value 56.70B | Price to Sales(TTM) 9.17 | ||
Enterprise Value to Revenue 9.57 | Enterprise Value to EBITDA 39.76 | Shares Outstanding 1.17B | Shares Floating 656.33M |
Shares Outstanding 1.17B | Shares Floating 656.33M | ||
Percent Insiders - | Percent Institutions 0.01 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.